Vemurafenib: the first drug approved for BRAF-mutant cancer.

Bollag, Gideon; Tsai, James; Zhang, Jiazhong; Zhang, Chao; Ibrahim, Prabha; Nolop, Keith; Hirth, Peter

Bollag, Gideon; Tsai, James; Zhang, Jiazhong; Zhang, Chao; Ibrahim, Prabha; Nolop, Keith; Hirth, Peter.

Affiliation

Bollag G; Plexxikon, 91 Bolivar Drive, Berkeley, California 94710, USA. gbollag@plexxikon.com

Nat Rev Drug Discov ; 11(11): 873-86, 2012 Nov.

Article in En | MEDLINE | ID: mdl-23060265

Subject(s)

Antineoplastic Agents/therapeutic use; Indoles/therapeutic use; Melanoma/drug therapy; Skin Neoplasms/drug therapy; Sulfonamides/therapeutic use; Animals; Antineoplastic Agents/pharmacology; Drug Approval; Drug Design; European Union; Humans; Indoles/pharmacology; Melanoma/genetics; Melanoma/pathology; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf/genetics; Skin Neoplasms/genetics; Skin Neoplasms/pathology; Sulfonamides/pharmacology; United States; Vemurafenib

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Sulfonamides / Indoles / Melanoma / Antineoplastic Agents Limits: Animals / Humans Country/Region as subject: America do norte Language: En Journal: Nat Rev Drug Discov Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2012 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google